- Home
- BHF vs PTGX Comparison
BHF vs PTGX Comparison
Compare BHF & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BHF
- PTGX
- Stock Information
- Founded
- BHF 2016
- PTGX 2006
- Country
- BHF United States
- PTGX United States
- Employees
- BHF N/A
- PTGX N/A
- Industry
- BHF Life Insurance
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- BHF Finance
- PTGX Health Care
- Exchange
- BHF Nasdaq
- PTGX Nasdaq
- Market Cap
- BHF 3.4B
- PTGX 2.9B
- IPO Year
- BHF N/A
- PTGX 2016
- Fundamental
- Price
- BHF $58.86
- PTGX $53.34
- Analyst Decision
- BHF Hold
- PTGX Strong Buy
- Analyst Count
- BHF 10
- PTGX 9
- Target Price
- BHF $57.90
- PTGX $67.11
- AVG Volume (30 Days)
- BHF 574.4K
- PTGX 898.5K
- Earning Date
- BHF 08-06-2025
- PTGX 08-05-2025
- Dividend Yield
- BHF N/A
- PTGX N/A
- EPS Growth
- BHF N/A
- PTGX N/A
- EPS
- BHF 8.45
- PTGX 0.86
- Revenue
- BHF $8,610,000,000.00
- PTGX $207,801,000.00
- Revenue This Year
- BHF $41.29
- PTGX N/A
- Revenue Next Year
- BHF $2.39
- PTGX $47.15
- P/E Ratio
- BHF $6.95
- PTGX $62.27
- Revenue Growth
- BHF 165.09
- PTGX N/A
- 52 Week Low
- BHF $40.00
- PTGX $30.67
- 52 Week High
- BHF $64.12
- PTGX $60.60
- Technical
- Relative Strength Index (RSI)
- BHF 52.71
- PTGX 58.33
- Support Level
- BHF $57.51
- PTGX $54.48
- Resistance Level
- BHF $58.92
- PTGX $57.18
- Average True Range (ATR)
- BHF 1.55
- PTGX 2.04
- MACD
- BHF -0.10
- PTGX -0.09
- Stochastic Oscillator
- BHF 71.13
- PTGX 57.13
About BHF Brighthouse Financial Inc.
Brighthouse Financial Inc is a United States-based provider of annuity products and life insurance through independent distribution channels and marketing arrangements with distribution partners. Its segments are Annuities, Life, Run-off and Corporate and Other. It derives a majority of the revenue from the Annuities segment which includes variable, fixed, index-linked, and income annuities. The life segment includes variable, term, universal, and whole life policies.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.